- Home
- GEG vs STRO Comparison
GEG vs STRO Comparison
Compare GEG & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- STRO
- Stock Information
- Founded
- GEG 1994
- STRO 2003
- Country
- GEG United States
- STRO United States
- Employees
- GEG N/A
- STRO N/A
- Industry
- GEG Computer Software: Prepackaged Software
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GEG Technology
- STRO Health Care
- Exchange
- GEG Nasdaq
- STRO Nasdaq
- Market Cap
- GEG 54.1M
- STRO 50.0M
- IPO Year
- GEG N/A
- STRO 2018
- Fundamental
- Price
- GEG $1.91
- STRO $0.90
- Analyst Decision
- GEG
- STRO Buy
- Analyst Count
- GEG 0
- STRO 7
- Target Price
- GEG N/A
- STRO $6.83
- AVG Volume (30 Days)
- GEG 13.6K
- STRO 2.1M
- Earning Date
- GEG 05-07-2025
- STRO 05-12-2025
- Dividend Yield
- GEG N/A
- STRO N/A
- EPS Growth
- GEG N/A
- STRO N/A
- EPS
- GEG 0.00
- STRO N/A
- Revenue
- GEG $19,204,000.00
- STRO $62,043,000.00
- Revenue This Year
- GEG N/A
- STRO N/A
- Revenue Next Year
- GEG N/A
- STRO $1.29
- P/E Ratio
- GEG $17,949.65
- STRO N/A
- Revenue Growth
- GEG 73.75
- STRO N/A
- 52 Week Low
- GEG $1.70
- STRO $0.52
- 52 Week High
- GEG $2.04
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- GEG 52.22
- STRO 52.79
- Support Level
- GEG $1.76
- STRO $0.52
- Resistance Level
- GEG $1.95
- STRO $1.31
- Average True Range (ATR)
- GEG 0.06
- STRO 0.16
- MACD
- GEG 0.00
- STRO 0.08
- Stochastic Oscillator
- GEG 57.69
- STRO 48.43
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.